These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 25785645)

  • 1. Targeting α-synuclein oligomers by protein-fragment complementation for drug discovery in synucleinopathies.
    Moussaud S; Malany S; Mehta A; Vasile S; Smith LH; McLean PJ
    Expert Opin Ther Targets; 2015 May; 19(5):589-603. PubMed ID: 25785645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies.
    Sengupta U; Guerrero-Muñoz MJ; Castillo-Carranza DL; Lasagna-Reeves CA; Gerson JE; Paulucci-Holthauzen AA; Krishnamurthy S; Farhed M; Jackson GR; Kayed R
    Biol Psychiatry; 2015 Nov; 78(10):672-83. PubMed ID: 25676491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies.
    Ferrer I; Blanco R; Carmona M; Puig B; Barrachina M; Gómez C; Ambrosio S
    J Neural Transm (Vienna); 2001; 108(12):1383-96. PubMed ID: 11810403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha-Synuclein oligomerization and aggregation: All models are useful but only if we know what they model: This is the reply to a comment "Alpha-synuclein oligomerization and aggregation: A model will always be a model" on the original article "Monitoring alpha-synuclein oligomerization and aggregation using bimolecular fluorescence complementation assays: What you see is not always what you get". The articles are accompanied by a Preface "How good are cellular models?".
    Lashuel HA
    J Neurochem; 2021 May; 157(4):891-898. PubMed ID: 33336386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vivo Protein Complementation Demonstrates Presynaptic α-Synuclein Oligomerization and Age-Dependent Accumulation of 8-16-mer Oligomer Species.
    Kiechle M; von Einem B; Höfs L; Voehringer P; Grozdanov V; Markx D; Parlato R; Wiesner D; Mayer B; Sakk O; Baumann B; Lukassen S; Liss B; Ekici AB; Ludolph AC; Walther P; Ferger B; McLean PJ; Falkenburger BH; Weishaupt JH; Danzer KM
    Cell Rep; 2019 Nov; 29(9):2862-2874.e9. PubMed ID: 31775051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders.
    Lindström V; Ihse E; Fagerqvist T; Bergström J; Nordström E; Möller C; Lannfelt L; Ingelsson M
    Immunotherapy; 2014; 6(2):141-53. PubMed ID: 24491088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formation of toxic oligomeric alpha-synuclein species in living cells.
    Outeiro TF; Putcha P; Tetzlaff JE; Spoelgen R; Koker M; Carvalho F; Hyman BT; McLean PJ
    PLoS One; 2008 Apr; 3(4):e1867. PubMed ID: 18382657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-aggregation Effects of Phenolic Compounds on α-synuclein.
    Ono K; Tsuji M; Yamasaki TR; Pasinetti GM
    Molecules; 2020 May; 25(10):. PubMed ID: 32456274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Golgi-localized, gamma ear-containing, ARF-binding (GGA) protein family alters alpha synuclein (α-syn) oligomerization and secretion.
    von Einem B; Eschbach J; Kiechle M; Wahler A; Thal DR; McLean PJ; Weishaupt JH; Ludolph AC; von Arnim CAF; Danzer KM
    Aging (Albany NY); 2017 Jul; 9(7):1677-1697. PubMed ID: 28722658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies.
    Stuendl A; Kunadt M; Kruse N; Bartels C; Moebius W; Danzer KM; Mollenhauer B; Schneider A
    Brain; 2016 Feb; 139(Pt 2):481-94. PubMed ID: 26647156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-Synuclein Proximity Ligation Assay (AS-PLA) in Brain Sections to Probe for Alpha-Synuclein Oligomers.
    Roberts RF; Bengoa-Vergniory N; Alegre-Abarrategui J
    Methods Mol Biol; 2019; 1948():69-76. PubMed ID: 30771171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.
    Lawand NB; Saadé NE; El-Agnaf OM; Safieh-Garabedian B
    Expert Opin Ther Targets; 2015; 19(10):1351-60. PubMed ID: 26135549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease.
    Braithwaite SP; Stock JB; Mouradian MM
    Rev Neurosci; 2012 Mar; 23(2):191-8. PubMed ID: 22499677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-Synucleinopathy phenotypes.
    McCann H; Stevens CH; Cartwright H; Halliday GM
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S62-7. PubMed ID: 24262191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease.
    Wrasidlo W; Tsigelny IF; Price DL; Dutta G; Rockenstein E; Schwarz TC; Ledolter K; Bonhaus D; Paulino A; Eleuteri S; Skjevik ÅA; Kouznetsova VL; Spencer B; Desplats P; Gonzalez-Ruelas T; Trejo-Morales M; Overk CR; Winter S; Zhu C; Chesselet MF; Meier D; Moessler H; Konrat R; Masliah E
    Brain; 2016 Dec; 139(Pt 12):3217-3236. PubMed ID: 27679481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Alpha-Synuclein in blood and cerebrospinal fluid of patients with alpha-synucleinopathy].
    Ono K; Yamada M
    Rinsho Byori; 2014 Mar; 62(3):241-5. PubMed ID: 24800499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From Yeast to Humans: Leveraging New Approaches in Yeast to Accelerate Discovery of Therapeutic Targets for Synucleinopathies.
    Piotrowski JS; Tardiff DF
    Methods Mol Biol; 2019; 2049():419-444. PubMed ID: 31602625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy.
    Gerson JE; Farmer KM; Henson N; Castillo-Carranza DL; Carretero Murillo M; Sengupta U; Barrett A; Kayed R
    Mol Neurodegener; 2018 Mar; 13(1):13. PubMed ID: 29544548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.